Agilent Sells PCR Technology
This technology was not central to Agilent’s diagnostics business and will be welcomed by Third Wave. Third Wave settled its patent infringement suit against Stratagene last year, with Stratagene making a $10.75 million payment.
Madison, WI 5/30/08—Molecular diagnostics company Third Wave Technologies has agreed to acquire Stratagene’s Full Velocity patents and patent applications from Agilent Technologies. The Full Velocity patents cover quantitative PCR and quantitative real-time PCR chemistries. “Third Wave’s strategic acquisition of the Full Velocity patents cements an integral part of our clinical menu expansion plans and provides us valuable options in the research market,” commented Kevin T. Conroy, president and CEO of Third Wave Technologies. Third Wave estimates the quantitative PCR market to be worth $500 million.